ArticleCytotechnology2025
ELF3 regulates epithelial-mesenchymal transition through TPM1 and promotes the development of endometrial cancer.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is one of the common malignancies of the female reproductive system, and metastasis is critical to the progression and prognosis of EC. As a transcription factor, ELF3 is widely involved in the regulation of cancer cell growth and metastasis, but its role in EC is unclear. The purpose of this study was to explore the role and mechanism of ELF3 in regulating EC progression. In this study, we collected 8 pairs of EC tissue and normal paracancerous endometrial tissue, and injected human endometrial cancer cells (Ishikawa) into the left axilla of nude mice to construct a model of subcutaneous tumorigenesis in nude mice. The growth of Ishikawa cells and tumor tissues of EC nude mice was evaluated by CCK-8, clone formation assay, immunohistochemistry, etc., and the expression of related proteins and genes was detected by Western blot and RT-qPCR. In this study, it was found that the expression of ELF3 was up-regulated in EC, and knockdown of ELF3 could inhibit the proliferative activity and colony formation of EC cells, promote the expression of E-cadherin, inhibit the expression of N-cadherin and Vimentin, and reduce the epithelial-mesenchymal transition (EMT) of EC cells, thereby inhibiting the migration of EC cells to a certain extent and alleviating the development of EC in vivo. Mechanistically, ELF3 inhibits TPM1 transcription by binding to the promoter region of TPM1 gene, thereby inhibiting TPM1 expression, promoting EMT, proliferation and migration of EC cells, and accelerating the occurrence and development of EC in vivo. ELF3 promotes the development of EC through TPM1 regulation of EMT, and inhibition of ELF3 may become a potential new target for the treatment of EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.